213 results
8-K
EX-99.1
BLUE
Bluebird bio Inc
26 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:08pm
of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive
8-K
EX-99.1
BLUE
Bluebird bio Inc
26 Mar 24
Results of Operations and Financial Condition
7:03am
therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral … or actual events being different than bluebird’s assumptions; the risk that the efficacy and safety results from bluebird’s prior and ongoing clinical
8-K
EX-99.1
BLUE
Bluebird bio Inc
8 Jan 24
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8:03am
the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone … and safety results from bluebird’s prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that bluebird is not able
8-K
EX-99.2
BLUE
Bluebird bio Inc
8 Jan 24
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8:03am
Safety profile well-understood Differentiated attributes that matter to patients, payers and providers QTC network 35 QTCs ready to receive patient … months follow-up) and safety data from 54 patients* February 13, 2023 data cut showing: – 32 patients evaluable for VOE endpoints including 8 adolescent
424B5
BLUE
Bluebird bio Inc
20 Dec 23
Prospectus supplement for primary offering
5:05pm
since such process can be slower to reimburse.
S-8
Even if a product displays a favorable efficacy and safety profile in clinical studies, market
8-K
EX-1.1
nyc 487gol
20 Dec 23
Entry into a Material Definitive Agreement
7:42am
424B5
mixyz4f
18 Dec 23
Prospectus supplement for primary offering
5:07pm
8-K
l378lftvuf4g1bg
14 Dec 23
Regulation FD Disclosure
7:30am
8-K
uacj2k9 66zfs4
11 Dec 23
Regulation FD Disclosure
8:06am
8-K
EX-99.1
toa00us wn1mk
11 Dec 23
Regulation FD Disclosure
8:06am
8-K
EX-99.1
6d6q09g4082ny f4y8t
7 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
ucrliwcbwgu5 pc
30 Oct 23
Entry into a Material Definitive Agreement
8:05am
8-K
EX-1.1
etd35 pqoatfyb
8 Aug 23
Entry into a Material Definitive Agreement
9:05am
8-K
EX-99.1
f6ha9t
8 Aug 23
Regulation FD Disclosure
8:55am
8-K
EX-99.1
vxejk
8 Aug 23
Results of Operations and Financial Condition
7:02am
8-K
vmbqwhuu
12 Jul 23
Regulation FD Disclosure
12:00am
8-K
EX-99.1
lzkoh41w
12 Jul 23
Regulation FD Disclosure
12:00am